Ftse Mib
34.570,79
0,86%
DAX
18.524,31
0,58%
S&P 500
5.291,34
0,15%
NASDAQ
16.857,05
0,17%
Bitcoin
70.872,73
0,35%
Registration Strip Icon for discussion Registrati per interagire nei nostri forum attivi per discutere con investitori con idee simili.
Registrati

Quotazioni in diretta

Non abbiamo trovato risultati per:
Assicurati di aver scritto correttamente o prova ad allargare la ricerca.

Più Attivi

Toplist

Sembra che tu non sia connesso.
Clicca il pulsante qui sotto per accedere e visualizzare la tua cronologia recente.

Registrati

Sei già registrato? Accedi

Pepperstone

Inizia Ora

Pepperstone
Home Investire Azioni U.S.A. NASDAQ Peregrine Pharmaceuticals Inc. (MM) (PPHMD) Peregrine Pharmaceuticals Inc. (MM) (PPHMD) Notizie

PPHMD

Peregrine Pharmaceuticals Inc. (MM) (PPHMD)

HOME News News di Agenzia

News di Agenzia

Da:
 Ti mostriamo gli articoli più rilevanti per la tua ricerca:NASDAQ:PPHMD
DataOraFonteTitoloSimboloCompagnia
29/03/201923:42Business WireAnnouncing VanEck Vectors ETFs’ March 2019 DistributionsNASDAQ:PPHMDPeregrine Pharmaceuticals Inc. (MM)
27/12/201800:37Business WireAnnouncing VanEck Vectors Equity ETFs December 2018 DistributionNASDAQ:PPHMDPeregrine Pharmaceuticals Inc. (MM)
17/10/201817:48Business WireVanEck Launches ESPO, ETF Focused on Fast Growing Video Game and eSports IndustryNASDAQ:PPHMDPeregrine Pharmaceuticals Inc. (MM)
29/09/201800:03Business WireAnnouncing VanEck Vectors Equity ETFs’ September 2018 DistributionsNASDAQ:PPHMDPeregrine Pharmaceuticals Inc. (MM)
30/06/201800:15Business WireAnnouncing VanEck Vectors Equity ETFs June 2018 DistributionsNASDAQ:PPHMDPeregrine Pharmaceuticals Inc. (MM)
29/03/201823:58Business WireAnnouncing VanEck Vectors Equity ETFs March 2018 DistributionsNASDAQ:PPHMDPeregrine Pharmaceuticals Inc. (MM)
10/11/200915:30PR Newswire (US)New Study in Clinical Cancer Research Shows Therapeutic Promise of Peregrine's Bavituximab With Radiation in a Lethal Brain CancNASDAQ:PPHMDPeregrine Pharmaceuticals Inc. (MM)
04/11/200920:17PR Newswire (US)Peregrine Pharmaceuticals Awarded Second Broad U.S. Patent for Anti-Viral Applications of Phospholipid-Targeting AntibodiesNASDAQ:PPHMDPeregrine Pharmaceuticals Inc. (MM)
03/11/200921:00PR Newswire (US)Peregrine Pharmaceuticals Regains Full Compliance With Nasdaq Continued Listing RequirementsNASDAQ:PPHMD
27/10/200913:17Edgar (US Regulatory)Current report filing (8-K)NASDAQ:PPHMDPeregrine Pharmaceuticals Inc. (MM)
23/10/200923:34Edgar (US Regulatory)Statement of Changes in Beneficial Ownership (4)NASDAQ:PPHMDPeregrine Pharmaceuticals Inc. (MM)
21/10/200915:30PR Newswire (US)Peregrine Pharmaceuticals Reports 61% Objective Response Rate in 46-Patient Bavituximab Phase II Trial in Advanced Breast CancerNASDAQ:PPHMD
19/10/200915:30PR Newswire (US)Peregrine Pharmaceuticals Appoints Former Genentech Senior Executive Dr. Robert Garnick as Head of Regulatory AffairsNASDAQ:PPHMD
19/10/200914:30PR Newswire (US)Peregrine Pharmaceuticals 1:5 Reverse Stock Split Takes EffectNASDAQ:PPHMD
 Ti mostriamo gli articoli più rilevanti per la tua ricerca:NASDAQ:PPHMD

La tua Cronologia

BIT
P1Y409
NLBNPIT1Y409 20351221 49...
LSE
FHI
Delayed Upgrade Clock
Per accedere al tempo reale push di Borsa è necessario registrarsi.

Il sito ADVFN Italia è stato realizzato ed è gestito da PRODESFIN su licenza di ADVFN PLC.

PER CONTATTI E PUBBLICITA' SUL SITO CLICCARE QUI

Accedendo ai servizi offerti da ADVFN, ne si accettano le condizioni generali Termini & Condizioni

ADVFN Network